Skip to main content
Premium Trial:

Request an Annual Quote

Quantgene, CureMatch Partner to Guide Precision Cancer Treatment

NEW YORK – Quantgene and CureMatch said on Wednesday that they have signed a strategic partnership to integrate genomic, cloud, and artificial intelligence technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer.

The firms also said that they plan to collaborate on advancing genomics and AI-guided oncology tools. 

Santa Monica, California-based Quantgene said its Quantgene Liquid assay profiles cell-free DNA in blood samples from cancer patients to establish their mutational profiles.

"Deep genomics and AI can be a game-changer for cancer patients, [as] new combination treatments can significantly improve outcomes," Jo Bhakdi, founder and CEO of Quantgene, said in a statement. "With CureMatch, we can make precision treatment insights available to everyone through a simple blood draw."

San Diego-based CureMatch's Decision Support System leverages proprietary algorithms, as well as curated clinical and scientific knowledge to provide a matching score to help doctors identify combinations and monotherapies for optimal cancer treatment.

By integrating both technologies, the firms believe patients and oncologists will have access to a workflow that only requires a blood draw to match them to appropriate cancer therapies. Patients will be able to receive results from the combined workflow in as little as three weeks from a blood draw.

Financial details of the agreement were not disclosed.

"[Quantgene's] ability to unlock the human genome and further inform our decision support system for oncology complements the CureMatch precision medicine solution and supports our mission to extend and save lives."

Quantgene previously partnered with Viktor Scientific in February to launch a genomics health service.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.